145 related articles for article (PubMed ID: 35732976)
1. Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.
Wolach O; Frisch A; Shargian L; Yeshurun M; Apel A; Vainstein V; Moshe Y; Shimony S; Amit O; Bar-On Y; Ofran Y; Raanani P; Nachmias B; Ram R
Ann Hematol; 2022 Aug; 101(8):1719-1726. PubMed ID: 35732976
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
Zucenka A; Vaitekenaite V; Maneikis K; Davainis L; Pileckyte R; Trociukas I; Peceliunas V; Zvirblis T; Staras V; Griskevicius L
Bone Marrow Transplant; 2021 Nov; 56(11):2804-2812. PubMed ID: 34274954
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review.
Sherban A; Fredman D; Shimony S; Yeshurun M; Raanani P; Stahl M; Gafter-Gvili A; Wolach O
Leuk Res; 2023 Oct; 133():107368. PubMed ID: 37598660
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Tenold ME; Moskoff BN; Krishnan R; Rosenberg AS; Hoeg RT; Abedi M; Tuscano JM; Jonas BA
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax is safe and efficacious in relapsed/refractory AML.
Ganzel C; Ram R; Gural A; Wolach O; Gino-Moor S; Vainstein V; Nachmias B; Apel A; Koren-Michowitz M; Pasvolsky O; Yerushalmi R; Danylesko I; Cohen Y; Peretz G; Moshe Y; Zektser M; Yeganeh S; Rowe JM; Ofran Y
Leuk Lymphoma; 2020 Sep; 61(9):2221-2225. PubMed ID: 32420775
[TBL] [Abstract][Full Text] [Related]
10. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Shahswar R; Beutel G; Gabdoulline R; Schwarzer A; Kloos A; Koenecke C; Stadler M; Gohring G; Behrens YL; Li Z; Dallmann LK; Klement P; Albert C; Wichmann M; Alwie Y; Benner A; Saadati M; Ganser A; Thol F; Heuser M
Haematologica; 2024 Jan; 109(1):72-83. PubMed ID: 37470150
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
[TBL] [Abstract][Full Text] [Related]
14. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
[No Abstract] [Full Text] [Related]
15. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
16. [Venetoclax Combined with CACAG Regimen in the Treatment of Patients with Refractory/Relapse Acute Myeloid Leukemia: A Prospective Clinical Study].
Gao WJ; Yang JJ; Li M; Wen YN; Jiao YF; LE N; Liu YC; Wang N; Huang S; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):90-95. PubMed ID: 38387905
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies.
Zucenka A; Pileckyte R; Trociukas I; Peceliunas V; Vaitekenaite V; Maneikis K; Davainis L; Zvirblis T; Stoskus M; Gineikiene E; Norvilas R; Dirse V; Surauciute A; Zucenkiene E; Griskevicius L
Eur J Haematol; 2021 Jan; 106(1):105-113. PubMed ID: 32997830
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.
Amit O; On YB; Perez G; Shargian-Alon L; Yeshurun M; Ram R
Ann Hematol; 2021 Mar; 100(3):817-824. PubMed ID: 33442793
[TBL] [Abstract][Full Text] [Related]
19. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
